Two large, parallel trials with 107 sites spread across the United States. Heavy competition for patients because of multiple competing treatments already on the market. And an advertising strategy that needed to attract more than 1,400 subjects fast enough to meet the sponsor’s aggressive schedule.
Those were just some of the challenges we faced when studying a topical drug to treat rosacea. And as with most complex problems, the strategy required a broad set of solutions and experience-based insights.
Study Description: Phase III study of a topical treatment for rosacea
Therapeutic Area: Dermatology
Geographic Scope: 107 sites in the United States
Patient Population: More than 1,400 patients
Length of Enrollment Period: Twelve months
Outcome: Phase III trial completed and results are pending submission to FDA